PPT-CV Risk of SU and Insulin

Pharmacoepidemiology and Drug Safety 200817753759 So benefit of both SUInsulin in research studies UKPDS DCCTEDIC But adverse risk in real world use Link between hypoglycemia and acute cardiovascular events in type 2 diabetes. Dr. Neil Munro, . Esher. , . United Kingdom. Socio-economic consequences of major hypoglycaemia in T1D and T2D. T1D: 1.1–3.2 major hypoglycaemic events/year. 1. T2D: 0.1–0.7 severe hypoglycaemic events/year (treatment dependent). Hypoglycaemic. Agents. Outline. What are the available OHG agents and how do they work?. Metformin – how much, and how safe?. Can I still use TZDS (glitazones)?. What is the place of acarbose?. Suggested algorithm for initiating OHG. 24. th. November 2016. Andrew Gallagher. Consultant Physician. and Endocrinologist. NHS Greater Glasgow & Clyde. Prevalence – 2015 data. WORLDWIDE. . Almost 300 million people with diabetes aged 20-79. Early work indicated ponies grazing high NSC pastures and having characteristics such as IR and obesity Were at greater risk of laminitis. . Resting . hyperinsulinaemia. predicts recurrence of laminitis in ponies on pasture. . T1DM- LIKE autoimmune diabetes- . I. nsulitis . The . class I MHC molecules are . hyperexpressed. on the β-cell surface in T1D patients making β-cells more . susceptible to cytotoxic lymphocyte (CTL)-mediated destruction. . Pharmacoepidemiology and Drug Safety. 2008;(17):753-759.. So benefit of both SU/Insulin in. research studies –UKPDS, DCCT/EDIC. But adverse risk in ‘real world’ use. Link between hypoglycemia and acute cardiovascular events in type 2 diabetes. Rose M. Flinchum, MSEd., MS, CNS, RN, ACNS-BC, BC-ADM, CDE. Inpatient Diabetes CNS / Certified Diabetes Educator. Outpatient DSMES Quality Coordinator. Diabetes in our Practices. 2015 Statistics. 30.3 million Americans; 9.4% of the population. Ching Yee Ngan. Practice Support Pharmacist. City and Hackney CCG. ching-yee.ngan@nhs.net. Learning objectives. Type 2 diabetes recap and complications. Management of type 2 diabetes. Non-pharmacological, including diet. David J Albrecht D.O.. Heart & Vascular 2018 Winter Conference. Cardiovascular risk . m. odification in relation to current diabetes management . therapies. Case study highlighting the therapeutic decisions . k, HCntl3B i Ut iuiRg(l ,tRlaSU k,3B )SgCaEClCR B SSgCCB k R CsB 77 kCs 7y5FCu,t .atCl,s kt iuC Su, &#x November 2016. Andrew Gallagher. Consultant Physician. and Endocrinologist. NHS Greater Glasgow & Clyde. Prevalence – 2015 data. WORLDWIDE. . Almost 300 million people with diabetes aged 20-79. Lt Col Prof Dr Shakeel Ahmed Mirza. MBBS, MRCP ( UK ), FRCP ( London ). Classified Medical Specialist. Gastroenterologist MH . Rwp. . Hepatologist & Endocrinologist. Prof of Medicine. AFPGMI. Layout. Soheila. . Sadeghi. What is the diagnosis ?. What are the differences between MODY and type 1 , 2 DM ?. MODYs subtypes?. Indications for genetic testing ?. What are the Benefits of Diagnosing MODY?. Type1 D.M:. -. . formerly known as juvenile-onset or IDDM. -Absolute insulin deficiency . -increased risk of chronic micro vascular disease at an early age . Types:. Type2 D.M:. -. . formerly known adult onset or NIDDM.